# Identification and Validation of Noninvasive Biomarkers of the Diagnosis and Severity of NASH in Type 2 Diabetics

> **NCT03634098** · NA · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 970 (actual)

## Conditions studied

- Type2 Diabetes

## Interventions

- **DEVICE:** new quantitative imaging techniques with contast products
- **DIAGNOSTIC_TEST:** blood sample
- **DIAGNOSTIC_TEST:** second generation tests

## Key facts

- **NCT ID:** NCT03634098
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-25
- **Primary completion:** 2022-07-31
- **Final completion:** 2022-09-30
- **Target enrollment:** 970 (ACTUAL)
- **Last updated:** 2022-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03634098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03634098, "Identification and Validation of Noninvasive Biomarkers of the Diagnosis and Severity of NASH in Type 2 Diabetics". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03634098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*